Unlabelled: The serum level of the human cathelicidin-LL37, an immunomodulatory vitamin D-induced peptide was less studied in viral hepatitis. The aim of this study was to analyse the cathelicidin-LL37 and vitamin D serum level in hepatitis B virus (HBV) and hepatitis C virus (HCV) infections and their correlations.
Methods: A total of 52 patients with HBV and HCV hepatitis and 22 controls were selected. ELISA method was used to detect the cahelicidin-LL37 (LL37 human Elisa Hycult Biotech) and 25-hydroxyvitamin D (IDS 25-Hydroxy Vitamin D EIA Immunodiagnostic Systems Ltd) serum level. The positive viral load (obtained following RT-PCR) defined active forms of hepatitis whereas a negative viral load indicated inactive hepatitis. Cathelicidin-LL37 and vitamin D were analysed in each group of hepatitis versus controls and each active hepatitis group versus inactive hepatitis group.
Results: Increased LL37 plasma levels were noted in HCV hepatitis versus controls (p = 0.046), HBV hepatitis versus controls (p = 0.087), active versus inactive HCV hepatitis (p = 0.014) and inactive versus active HBV hepatitis (p = 0.009). Vitamin D deficiency (< 31.80 +/- 8.74 nmol/L) was detected in all the subjects. The Pearson correlation between the vitamin D status and LL37 level was weak.
Conclusions: Plasma concentrations of cathelicidin-LL37 were significantly higher in active HCV and inactive HBV infection suggesting the LL37 implication in certain HCV and HBV hepatitis forms. Vitamin D deficiency was uniformly observed in all forms of hepatitis but with no significant correlation to the LL37 level.
Download full-text PDF |
Source |
---|
J Infect Dev Ctries
December 2024
Department of Paediatrics, University of Calabar, Calabar, Cross River State, Nigeria.
Introduction: Globally, approximately 2.7 million and 2.3 million people living with HIV are co-infected with hepatitis B and C virus, respectively.
View Article and Find Full Text PDFGenomic and evolutionary analysis of epidemic porcine hepatitis E virus (HEV) in the Tibetan Plateau was performed. Faecal samples were collected from 216 Tibetan pigs and 78 Tibetan Yorkshire (Large White) and 53 tissue samples from Yorkshire from the Linzhi City slaughterhouse. Total RNA was extracted from faeces and fragments of HEV open reading frame 2 (ORF2) detected by reverse transcription and nested polymerase chain reaction (RT-nPCR) and cloned.
View Article and Find Full Text PDFOncologist
January 2025
Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
Immune checkpoint inhibitors (ICIs) have advanced the treatment of metastatic melanoma. However, some patients develop ICI-associated toxicities like hepatitis (ie, immune-mediated hepatitis; IMH). Although these toxicities usually resolve with steroids, steroid-refractory events may occur, which may be a major source of morbidity and mortality without obviously defined treatment algorithms.
View Article and Find Full Text PDFJ Viral Hepat
February 2025
Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
Using a systematic review and meta-analytic approach, this study determined the durability of HBV immunity and the prevalence of anamnestic response to a booster HBV vaccine dose in individuals previously vaccinated with a 3-dose HBV vaccine series as children or adolescents. Two researchers independently searched PubMed, Embase and Cochrane from inception to 6/1/2023 and performed data extraction. Studies that included individuals with significant comorbidities or < 5 years of follow-up were excluded.
View Article and Find Full Text PDFJ Am Coll Surg
January 2025
Cincinnati Research in Outcomes and Safety in Surgery (CROSS) Research Group. Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Background: Long-term outcomes of HBV nucleic acid test (NAT)-positive (+) allograft use in seronegative liver transplant (LT) and kidney transplant (KT) recipients remains unknown despite being incorporated into practice by select centers. This study compares long-term outcomes between HBV NAT+ and NAT-negative (-) allografts in seronegative recipients.
Study Design: All recipients of an HBV core antibody-positive (HBcAb+) LT or KT were prospectively evaluated at a single transplant center from 6/2015-3/2023 and compared by NAT status.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!